BioPharmaChem Ireland names Tim Shanahan as its new chair

Tim Shanahan, VP for external manufacturing operations at Ipsen, is elected as chair of Ibec's biopharma group

Tim Shanahan, VP of Ipsen, chair of BioPharmaChem.

Tim Shanahan, VP for external manufacturing operations at Ipsen, has been elected as chair of BioPharmaChem Ireland (BPCI), the Ibec group representing the biopharmaceutical and chemical sectors in Ireland.

Tim succeeds outgoing chair, Joyce Fitzharris, president of SK pharmteco, Small Molecule, Europe.

Tim said: “It is a huge honour to be appointed chair of BPCI as Ireland prepares for its presidency of the Council of the European Union. There is a real opportunity to strengthen Europe’s competitiveness in life sciences, from securing resilient supply chains and advancing innovation, to ensuring the right policy environment for continued investment in manufacturing and R&D.” 

Mr Shanahan thanked Joyce Fitzharris for the work she has done throughout her term. He said he would work to ensure Ireland remains a leading global location for the development and supply of medicines.

Sinead Keogh, director of BioPharmaChem Ireland and Ibec’s head of sectors, said: “Tim’s depth of experience will be invaluable as we continue to support our members, strengthen industry collaboration, and ensure the sector remains well positioned for continued growth and investment in Ireland.” 

The BPCI board is made up of executive directors at CEO and managing director level from across the biopharma, pharma, and chemical sectors. The biopharma and pharma industries in Ireland employ over 80,000 people directly and indirectly, across 90 companies.